Laurie Sehn

12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al.
11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
7:45
Novel targets and agents for lymphoma
John Kuruvilla et al.
5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
Novel lymphoma targets and agents
Andrew Zelenetz et al.
3:06
Results of trial on the use of interim PET scan to identify DLBCL
Laurie Sehn
1:34
The standard of care for DLBCL and double-hit lymphoma
Laurie Sehn
1:06
Recognizing the heterogeneity of DLBCL
Laurie Sehn
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals